Prolongation of QT interval is a rare adverse event, potentially leading to torsades de pointes reported with some oncological drugs and with 5-HT3-RA antiemetics.

In particular effect on QT interval with ondansetron is dose and time depending and can be avoided by reducing the dose administered and prolonging the infusion duration.

Safety concerns about other antiemetics such as granisetron, dolasetron, and metoclopramide have been raised.

Oncologist and cardiologist should integrate their knowledge and cooperate in a collaborative fashion to monitor their patients and select high-risk patients who have to be spared QT prolonging drugs.